ResMed Inc (RMD) - Net Assets
Based on the latest financial reports, ResMed Inc (RMD) has net assets worth $6.49 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.78 Billion) and total liabilities ($2.29 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ResMed Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.49 Billion |
| % of Total Assets | 73.9% |
| Annual Growth Rate | 26.92% |
| 5-Year Change | 106.81% |
| 10-Year Change | 252.12% |
| Growth Volatility | 72.14 |
ResMed Inc - Net Assets Trend (1993–2025)
This chart illustrates how ResMed Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is ResMed Inc worth.
Annual Net Assets for ResMed Inc (1993–2025)
The table below shows the annual net assets of ResMed Inc from 1993 to 2025. Also explore ResMed Inc annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $5.97 Billion | +22.69% |
| 2024-06-30 | $4.86 Billion | +17.78% |
| 2023-06-30 | $4.13 Billion | +22.89% |
| 2022-06-30 | $3.36 Billion | +16.46% |
| 2021-06-30 | $2.89 Billion | +15.56% |
| 2020-06-30 | $2.50 Billion | +20.50% |
| 2019-06-30 | $2.07 Billion | +0.64% |
| 2018-06-30 | $2.06 Billion | +5.04% |
| 2017-06-30 | $1.96 Billion | +15.66% |
| 2016-06-30 | $1.69 Billion | +6.77% |
| 2015-06-30 | $1.59 Billion | -9.72% |
| 2014-06-30 | $1.76 Billion | +9.17% |
| 2013-06-30 | $1.61 Billion | +0.18% |
| 2012-06-30 | $1.61 Billion | -7.11% |
| 2011-06-30 | $1.73 Billion | +34.42% |
| 2010-06-30 | $1.29 Billion | +15.45% |
| 2009-06-30 | $1.12 Billion | +3.09% |
| 2008-06-30 | $1.08 Billion | +16.17% |
| 2007-06-30 | $931.22 Million | +26.16% |
| 2006-06-30 | $738.15 Million | +55.71% |
| 2005-06-30 | $474.06 Million | +31.14% |
| 2004-06-30 | $361.50 Million | +26.21% |
| 2003-06-30 | $286.43 Million | +48.46% |
| 2002-06-30 | $192.93 Million | +92.23% |
| 2001-06-30 | $100.37 Million | +6.80% |
| 2000-06-30 | $93.97 Million | +31.23% |
| 1999-06-30 | $71.61 Million | +40.97% |
| 1998-06-30 | $50.80 Million | +13.90% |
| 1997-06-30 | $44.60 Million | +14.36% |
| 1996-06-30 | $39.00 Million | +34.95% |
| 1995-06-30 | $28.90 Million | +416.07% |
| 1994-06-30 | $5.60 Million | +93.10% |
| 1993-06-30 | $2.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ResMed Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 868684.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $6.08 Billion | 101.90% |
| Common Stock | $761.00K | 0.01% |
| Other Comprehensive Income | $-74.70 Million | -1.25% |
| Total Equity | $5.97 Billion | 100.00% |
ResMed Inc Competitors by Market Cap
The table below lists competitors of ResMed Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Telefonaktiebolaget LM Ericsson (publ)
F:ERCA
|
$27.92 Billion |
|
Bank Rakyat Indonesia Persero
JK:BBRI
|
$27.97 Billion |
|
SEVEN+I HLDGS UNSP.ADR1/2
F:S6MA
|
$27.98 Billion |
|
Ryanair Holdings plc
IR:RYA
|
$28.00 Billion |
|
RYANAIR HLDGS ADR NEW/5
F:RY4D
|
$27.87 Billion |
|
Willis Towers Watson PLC
NASDAQ:WTW
|
$27.78 Billion |
|
SHINHAN FINL ADR/1 SW5000
F:KSF1
|
$27.77 Billion |
|
Fortis Inc
TO:FTS
|
$27.76 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ResMed Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,864,043,000 to 5,967,859,000, a change of 1,103,816,000 (22.7%).
- Net income of 1,400,723,000 contributed positively to equity growth.
- Dividend payments of 310,880,000 reduced retained earnings.
- Share repurchases of 300,025,000 reduced equity.
- New share issuances of 74,439,000 increased equity.
- Other comprehensive income increased equity by 176,830,000.
- Other factors increased equity by 62,729,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.40 Billion | +23.47% |
| Dividends Paid | $310.88 Million | -5.21% |
| Share Repurchases | $300.02 Million | -5.03% |
| Share Issuances | $74.44 Million | +1.25% |
| Other Comprehensive Income | $176.83 Million | +2.96% |
| Other Changes | $62.73 Million | +1.05% |
| Total Change | $- | 22.69% |
Book Value vs Market Value Analysis
This analysis compares ResMed Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3674.48x to 5.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-06-30 | $0.06 | $222.00 | x |
| 1994-06-30 | $0.11 | $222.00 | x |
| 1995-06-30 | $0.41 | $222.00 | x |
| 1996-06-30 | $0.35 | $222.00 | x |
| 1997-06-30 | $0.38 | $222.00 | x |
| 1998-06-30 | $0.42 | $222.00 | x |
| 1999-06-30 | $0.58 | $222.00 | x |
| 2000-06-30 | $0.73 | $222.00 | x |
| 2001-06-30 | $0.75 | $222.00 | x |
| 2002-06-30 | $1.42 | $222.00 | x |
| 2003-06-30 | $2.08 | $222.00 | x |
| 2004-06-30 | $2.57 | $222.00 | x |
| 2005-06-30 | $3.16 | $222.00 | x |
| 2006-06-30 | $4.78 | $222.00 | x |
| 2007-06-30 | $5.95 | $222.00 | x |
| 2008-06-30 | $6.87 | $222.00 | x |
| 2009-06-30 | $7.23 | $222.00 | x |
| 2010-06-30 | $8.30 | $222.00 | x |
| 2011-06-30 | $11.01 | $222.00 | x |
| 2012-06-30 | $10.77 | $222.00 | x |
| 2013-06-30 | $11.00 | $222.00 | x |
| 2014-06-30 | $12.18 | $222.00 | x |
| 2015-06-30 | $11.12 | $222.00 | x |
| 2016-06-30 | $11.96 | $222.00 | x |
| 2017-06-30 | $13.76 | $222.00 | x |
| 2018-06-30 | $14.30 | $222.00 | x |
| 2019-06-30 | $14.34 | $222.00 | x |
| 2020-06-30 | $17.14 | $222.00 | x |
| 2021-06-30 | $19.70 | $222.00 | x |
| 2022-06-30 | $22.86 | $222.00 | x |
| 2023-06-30 | $28.01 | $222.00 | x |
| 2024-06-30 | $32.97 | $222.00 | x |
| 2025-06-30 | $40.50 | $222.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ResMed Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.47%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 27.22%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.37x
- Recent ROE (23.47%) is above the historical average (17.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 27.59% | 10.39% | 1.48x | 1.79x | $510.00K |
| 1994 | 21.43% | 8.63% | 1.45x | 1.71x | $640.00K |
| 1995 | 9.69% | 11.91% | 0.67x | 1.22x | $-90.00K |
| 1996 | 11.54% | 13.01% | 0.73x | 1.21x | $600.00K |
| 1997 | 16.82% | 15.24% | 0.90x | 1.23x | $3.04 Million |
| 1998 | 20.87% | 15.94% | 1.03x | 1.27x | $5.52 Million |
| 1999 | 22.49% | 18.17% | 0.99x | 1.26x | $8.94 Million |
| 2000 | 23.65% | 19.22% | 1.00x | 1.23x | $12.83 Million |
| 2001 | 11.59% | 7.50% | 0.54x | 2.87x | $1.59 Million |
| 2002 | 19.44% | 18.38% | 0.54x | 1.95x | $18.21 Million |
| 2003 | 15.96% | 16.72% | 0.60x | 1.60x | $17.09 Million |
| 2004 | 15.85% | 16.88% | 0.62x | 1.52x | $21.13 Million |
| 2005 | 13.67% | 15.23% | 0.55x | 1.63x | $17.38 Million |
| 2006 | 11.95% | 14.53% | 0.60x | 1.36x | $14.40 Million |
| 2007 | 7.12% | 9.26% | 0.57x | 1.34x | $-26.82 Million |
| 2008 | 10.20% | 13.20% | 0.59x | 1.30x | $2.13 Million |
| 2009 | 13.13% | 15.91% | 0.61x | 1.35x | $34.93 Million |
| 2010 | 14.76% | 17.40% | 0.67x | 1.26x | $61.33 Million |
| 2011 | 13.11% | 18.26% | 0.60x | 1.20x | $53.91 Million |
| 2012 | 15.85% | 18.62% | 0.64x | 1.33x | $94.09 Million |
| 2013 | 19.07% | 20.28% | 0.69x | 1.37x | $146.08 Million |
| 2014 | 19.64% | 22.20% | 0.66x | 1.34x | $169.45 Million |
| 2015 | 22.23% | 21.02% | 0.77x | 1.38x | $194.16 Million |
| 2016 | 20.79% | 19.17% | 0.56x | 1.92x | $182.92 Million |
| 2017 | 17.46% | 16.56% | 0.60x | 1.77x | $146.26 Million |
| 2018 | 15.33% | 13.49% | 0.76x | 1.49x | $109.69 Million |
| 2019 | 19.52% | 15.52% | 0.63x | 1.98x | $197.37 Million |
| 2020 | 24.90% | 21.02% | 0.64x | 1.84x | $371.97 Million |
| 2021 | 16.44% | 14.84% | 0.68x | 1.64x | $185.94 Million |
| 2022 | 23.19% | 21.78% | 0.70x | 1.52x | $443.36 Million |
| 2023 | 21.73% | 21.25% | 0.63x | 1.63x | $484.57 Million |
| 2024 | 20.99% | 21.79% | 0.68x | 1.41x | $534.55 Million |
| 2025 | 23.47% | 27.22% | 0.63x | 1.37x | $803.94 Million |
Industry Comparison
This section compares ResMed Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $846,677,900
- Average return on equity (ROE) among peers: -5.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ResMed Inc (RMD) | $6.49 Billion | 27.59% | 0.35x | $27.91 Billion |
| Akoya Biosciences Inc (AKYA) | $58.58 Million | -120.59% | 2.00x | $64.44 Million |
| Align Technology Inc (ALGN) | $581.32 Million | 10.10% | 0.30x | $10.51 Billion |
| AngioDynamics Inc (ANGO) | $405.75 Million | 2.00% | 0.08x | $631.15 Million |
| AptarGroup Inc (ATR) | $419.70 Million | 14.49% | 0.70x | $7.66 Billion |
| AtriCure Inc (ATRC) | $491.94 Million | -2.33% | 0.33x | $2.21 Billion |
| Avinger Inc (AVGR) | $-6.20 Million | 0.00% | 0.00x | $1.52 Million |
| Avantor Inc (AVTR) | $-3.05 Billion | 0.00% | 0.00x | $9.19 Billion |
| Azenta Inc (AZTA) | $2.53 Billion | -0.56% | 0.14x | $1.35 Billion |
| Baxter International Inc (BAX) | $6.23 Billion | 32.33% | 1.47x | $12.08 Billion |
| Becton Dickinson and Company (BDX) | $803.90 Million | 13.92% | 1.10x | $48.93 Billion |
About ResMed Inc
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, h… Read more